Stockscreener 앱 받기
0.2559
1.77%
-0.0046
시간 외 거래:
.28
0.0241
+9.42%
전일 마감가:
$0.2605
열려 있는:
$0.259
하루 거래량:
402.10K
Relative Volume:
0.23
시가총액:
$17.30M
수익:
-
순이익/손실:
$-18.65M
주가수익비율:
-0.5829
EPS:
-0.439
순현금흐름:
$-16.66M
1주 성능:
-24.76%
1개월 성능:
+1.87%
6개월 성능:
-51.93%
1년 성능:
-74.91%
1일 변동 폭
$0.24
$0.2633
1주일 범위
$0.24
$0.3891
52주 변동 폭
$0.2201
$1.53
Fibrobiologics Inc Stock (FBLG) Company Profile
명칭
Fibrobiologics Inc
전화
281-671-5150
주소
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.2559 | 17.61M | 0 | -18.65M | -16.66M | -0.439 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-30 | 개시 | H.C. Wainwright | Buy |
| 2024-09-24 | 개시 | Maxim Group | Buy |
Fibrobiologics Inc 주식(FBLG)의 최신 뉴스
FibroBiologics, Inc. 2025 Executive Compensation and Leadership Overview - Minichart
FibroBiologics (NASDAQ: FBLG) adds 2025 governance, pay and ownership details - Stock Titan
FibroBiologics: CYWC628 Drives Buy Rating on Strong Preclinical Wound and Burn Data in Large Underserved Markets - TipRanks
D. Boral Capital Reiterates 'Buy' Rating for FibroBiologics - National Today
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology - Bitget
Experimental cell-based treatment aims to speed healing for severe burns - Stock Titan
Gainers Report: Is FibroBiologics Inc benefiting from interest rate changesQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
FibroBiologics Updates CFO Compensation to Support Leadership - TipRanks
FibroBiologics sets new annual salary for CFO Jason D. Davis - Investing.com
FibroBiologics sets new annual salary for CFO Jason D. Davis By Investing.com - Investing.com Canada
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Sahm
FibroBiologics completes site onboarding for diabetic ulcer trial By Investing.com - Investing.com Canada
Top Executive Makes Bold Move Into FibroBiologics Stock - TipRanks
FibroBiologics completes site onboarding for diabetic ulcer trial - Investing.com
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
FibroBiologics (FBLG) CSO Khoja buys $11k in stock By Investing.com - Investing.com Australia
FibroBiologics Completes Site Onboarding for Phase 1/2 - GlobeNewswire
CEO Doubles Down on FibroBiologics With Bold Insider Stock Purchase - TipRanks
FBLG Earnings History & Surprises | EPS & Revenue Results | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FibroBiologics CFO Buys 70,000 Shares - National Today
CFO’s Bold Insider Buy Sparks Fresh Buzz Around FibroBiologics Stock - TipRanks
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock By Investing.com - Investing.com Australia
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock - Investing.com
FibroBiologics (FBLG) CFO purchases 70,000 shares in open-market trade - Stock Titan
FibroBiologics receives patent for osteoporosis cell therapy By Investing.com - Investing.com Canada
Insider Makes Bold New Bet on FibroBiologics Stock - TipRanks
FBLG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FibroBiologics Jumps 22% On New Osteoporosis Patent, Stock Up - Nasdaq
Garcia Ruben A, FibroBiologics general counsel, buys $13k in FBLG - Investing.com Australia
FibroBiologics receives patent for osteoporosis cell therapy - Investing.com
FibroBiologics, Inc. announces issuance of U.S. patent covering fibroblast cell therapy for the treatment of osteoporosis - marketscreener.com
Fibrobiologics, Inc. Announces Issuance Of U.S. Patent Covering Fibroblast Cell Therapy For The Treatment Of Osteoporosis - TradingView
FibroBiologics, Inc. Announces Issuance of U.S. Patent - GlobeNewswire
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis - Bitget
FBLG: Ready to Transition to Clinical-Stage Company - Smartkarma
FibroBiologics to Present at the BIO Investment & Growth Summit - Bitget
H.C. Wainwright cuts FibroBiologics stock price target to $4 By Investing.com - Investing.com Canada
H.C. Wainwright cuts FibroBiologics stock price target to $4 - Investing.com Nigeria
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Fibrobiologics Inc (FBLG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):